This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

American Pacific's CEO Discusses Divestiture Of In-Space Propulsion Business (Transcript)

I will now turn the call over to Joe.

Joseph Carleone

Thank you, Linda, and thank you ladies and gentlemen for joining our call. We are pleased to announce that we have entered an agreement to divest of our aerospace equipment segment, also known as AMPAC In-Space Propulsion, for $46 million in cash. With this divestiture AMPAC has a made a major strategic shift. We believe this will enhance the value of our corporation from many perspectives.

First of all, it will allow AMPAC to focus on the growth of our pharmaceutical business activity. We anticipate this focus will also lead to the enhancement of our financial performance as we continue to build upon our core capability and grow our pharmaceutical related product lines and exploit the potential of efficiencies among our reduced number of production sites.

Furthermore, the influx of cash as a result of this divestiture will allow us the flexibility of improving our balance sheet through reducing leverage and thereby position the company for future value added growth. Overall, aerospace and defense is forecasted to contract in certain segments and we expect consolidations to occur. Thus, you are either a buyer or a seller in the satellite space business as AMPAC ISP.

AMPAC In-Space Propulsion business flourished over the last few years and is poised to grow through expansion of its customer base and product lines both in the United States and in Europe. Achieving this next level of growth in this marketplace however will require support from a much larger player in the aerospace business. It became clear that AMPAC did not have the horsepower to adequately support both the pharmaceutical chemicals play and the aerospace play at the same time. Therefore we decided to monetize our investment in the satellite propulsion business to support the focused pursuit of the pharmaceutical business.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,704.46 +26.23 0.15%
S&P 500 2,057.62 +1.47 0.07%
NASDAQ 4,882.1770 +18.8150 0.39%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs